Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole interaction and extension study of oral LBH589 in advanced solid tumors
NL-OMON30887Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panobinostat and ketoconazole in Nonhematologic neoplasms and non-Hodgkin lymphoma (NHL), sponsored by Novartis. Primary endpoints: AUC0-tlast of LBH589, AUC0-infinity of LBH589 and 1 more. Started Oct 2007; status: active, not recruiting.
02
Drugs
panobinostatketoconazole
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON30887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30887.